Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

Completion of Target Enrollment Expected in Fourth Quarter

BERKELEY HEIGHTS, N.J., March 31 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the Data Safety Monitoring Board (DSMB) for AGENDA, a Phase 3 trial of Genasense (oblimersen sodium) Injection, which is the Company's lead oncology product, has recommended that the trial be continued as originally planned after initial review of blinded safety data from the study.

AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival.

At the end of the first quarter, the trial had accrued approximately 50 patients with approximately 60% of planned investigative sites having been initiated. Countries with sites currently open for enrollment include the U.S., Canada, Australia, France, Germany, Austria, and the Czech Republic. The trial is planned to open at approximately 90 sites worldwide, and most remaining sites are expected to initiate within the next 30 days. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.

"Investigator enthusiasm for AGENDA is quite high, and we are currently recruiting at our expected rate," said Dr. Loretta M. Itri, M.D., Genta's President, Pharmaceutical Development. "We believe the current rate, combin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 ... Tokio veranstalteten F&E-Tagung meldete ... zur Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot ... die fortgeschrittenen klinischen Programme und die Konzernstrategie ... Tagung bestand darin, aktuelle Meldungen zu den ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... The Pearland, Texas location of The Little ... four months to 12 years of age that offers everything ... parties and Summer Camps, is now under new ownership. , ... after spending over six years at The Little Gym ... , Berry has over ten years of experience working ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... common cause of death and disability in children and adolescents, ... a new study by UCLA researchers, the effects of a ... can linger for years. , Reporting in the May ... author and a UCLA post-doctoral fellow, and senior author Robert ...
... Ky., May 13 We,ve all made mistakes: bell bottoms, scrunchies ... in the past. Thanks to advances in skin care and ... In fact, it,s downright dangerous. According to the National Cancer ... in 2009 resulting in about 1,000 deaths. Skin cancer is ...
... was recently recognized by the Art Directors Club ... Awards Exhibition.ScienceFirst graphic designer Michelle Feingold won a ... a speaker training creative platform for a top-tier, ... received Certificates of Excellence. One of the entries ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
... ,Covering All the Bases® Hitting Challenge, during Major League Baseball,s ,4ALS ... famous ,Luckiest Man, farewell speech as he battled the disease that ... ... (Vocus) May 13, 2009 -- The ALS Association,s is launching the ...
... technology leader in email and file archiving ... and storage management, today announces the release ... Suite with SharePoint Archiving at Microsoft TechEd ... Email & File Archive Enterprise Suite with ...
Cached Medicine News:Health News:UCLA study shows traumatic brain injury haunts children for years 2Health News:Get Sun Smart at the Spa 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 2Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 2Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 4Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 5
... The 9101-7.5 convex array is designed with ... resolution obtained with this multi-frequency transducer is ... in need of quick and accurate diagnoses. ... versatility you need, and allows you to ...
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... light source is a superior choice for ... surgery, headlamps, and dental curing. This is ... light weight, compact and cost competitve with ... light source utilizes the latest in Cermax ...
... AtheNA Multi-Lyte Test System* is a ... simultaneously perform multiple assays from a ... It offers a simple and streamlined ... providing improved clinical sensitivity and comparable ...
Medicine Products: